1-(9-ethylcarbazol-3-yl)-N-(pyridin-3-ylmethyl)methanamine | 880813-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(9-ethylcarbazol-3-yl)-N-(pyridin-3-ylmethyl)methanamine
• CAS: 880813-30-9
• 化学式: C₂₁H₂₁N₃
• 分子量: 315.418
• InChiKey: GAVUWQFIRGBDHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氨甲基吡啶 、 N-乙基咔唑-3-甲醛 在 sodium cyanoborohydride 、 zinc(II) chloride 作用下， 以 甲醇 为溶剂， 生成 1-(9-ethylcarbazol-3-yl)-N-(pyridin-3-ylmethyl)methanamine
  参考文献：
  名称：

  [EN] COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT
  [FR] COMPOSITIONS ET MÉTHODES DE DÉTECTION ET DE TRAITEMENT DU CANCER

  摘要：

  本文公开了癌症检测和治疗的组合物和方法。考虑到抑制PRMT5的化合物，以及包含至少一种PRMT5抑制剂的治疗有效量的制药组合物。在某些实施例中，还考虑了包含至少一种HDAC抑制剂的制药组合物。本文还公开了通过向哺乳动物投与PRMT5抑制剂的治疗有效量来抑制PRMT5以治疗哺乳动物中的疾病的方法。

  公开号：

  WO2011079236A1

文献信息

• Compositions and Methods for Cancer Detection and Treatment
  申请人：Baiocchi Robert

  公开号：US20130059892A1

  公开（公告）日：2013-03-07

  Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.
• COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT
  申请人：Ohio State Innovation Foundation

  公开号：US20160052910A1

  公开（公告）日：2016-02-25

  Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.
• US9044432B2
  申请人：——

  公开号：US9044432B2

  公开（公告）日：2015-06-02
• US9676749B2
  申请人：——

  公开号：US9676749B2

  公开（公告）日：2017-06-13
• [EN] COMPOSITIONS AND METHODS FOR CANCER DETECTION AND TREATMENT<br/>[FR] COMPOSITIONS ET MÉTHODES DE DÉTECTION ET DE TRAITEMENT DU CANCER
  申请人：UNIV OHIO STATE RES FOUND

  公开号：WO2011079236A1

  公开（公告）日：2011-06-30

  Disclosed herein are compositions and methods for cancer detection and treatment. Compounds that inhibit PRMT5 are contemplated, as are pharmaceutical compositions comprising a therapeutically effective amount of at least one PRMT5 inhibitor. In some embodiments pharmaceutical compositions further comprising at least one HDAC inhibitor are contemplated. Methods of treating disorders in a mammal by inhibiting PRMT5 by administering to a mammal, a therapeutically effective amount of a PRMT5 inhibitor are also disclosed.

  本文公开了癌症检测和治疗的组合物和方法。考虑到抑制PRMT5的化合物，以及包含至少一种PRMT5抑制剂的治疗有效量的制药组合物。在某些实施例中，还考虑了包含至少一种HDAC抑制剂的制药组合物。本文还公开了通过向哺乳动物投与PRMT5抑制剂的治疗有效量来抑制PRMT5以治疗哺乳动物中的疾病的方法。